BBT-877, Single dose
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Bridge Biotherapeutics, Inc.
Overview
BBT-877, Single dose is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
BBT-877, Single dose clinical trials
Explore related
Medical disclaimer. This page summarizes research about BBT-877, Single dose for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.